• Skip to primary navigation
  • Skip to main content
SRI logo
  • About
    • Press room
    • Our history
  • Expertise
    • Advanced imaging systems
    • Artificial intelligence
    • Biomedical R&D services
    • Biomedical sciences
    • Computer vision
    • Cyber & formal methods
    • Education and learning
    • Innovation strategy and policy
    • National security
    • Ocean & space
    • Quantum
    • Robotics, sensors & devices
    • Speech & natural language
    • Video test & measurement
  • Ventures
  • NSIC
  • Careers
  • Contact
  • 日本支社
Search
Close
Case study June 14, 2021

Targeted Antigen Loaded Liposomes (TALL)

SRI scientists exploit the human immune response to target cancer cells and extend the benefits of cancer immunotherapies.


THE CHALLENGE

The potential and impact of cancer immunotherapies has – so far – been limited by low response rates, side effects and cost.

THE SOLUTION

SRI’s Targeted Antigen Loaded Liposomes (TALL), a new immunotherapy with the potential to overcome these challenges and extend the benefits of immunotherapy to many more patients.

The human immune system acts as a precision military force, seeking out and eliminating foreign invaders such as viruses, bacteria and cancer cells. In the case of cancer, immunotherapies that stimulate and reinforce this natural defense system are quickly emerging as first-line treatment for multiple tumor types. While they’ve contributed significantly to some patients’ survival, these therapies have limitations. In addition to high cost and potentially serious side effects, they work only for a specific and still fairly limited group of patients.

SRI Biosciences developed TALL as a means to trick the immune system into recognizing tumor cells as pathogen-infected cells. Essentially, TALL makes cancer cells look like they have the measles, exploiting the biological phenomenon known as recall immunity to encourage the human immune system to seek out and kill an invader it already knows how to fight.

SRI created TALL using the company’s novel FOX Three platform, which was developed to solve another critical drug development challenge: biotherapeutic compounds that have traditionally been difficult to deliver to the inside of cells and therefore make the targets inside those cells undruggable. FOX Three employs proprietary processes to identify unique peptide delivery agents (known as Molecular Guidance Systems, or MGS) that home to targeted cell types and deliver a therapeutic payload in a cell-specific fashion.

How it works

SRI scientists pack a synthetic peptide derived from the measles virus into neutral, stealth particles known as liposomes. They then attach tumor-targeting FOX Three MGSs to the surfaces of the liposomes. The MGSs home to tumor cells and, once there, the liposomes are transported into the tumor cells. The measles-derived peptide is then released inside the diseased cells and eventually presented on their surfaces, flagging them for the immune system. The measles ‘infected’ tumor cells are then targeted and killed by memory T cells, and the patient’s immune system clears the tumor.

The vast majority of humans worldwide have been vaccinated for measles, so the immune system already recognizes TALL and is primed to respond to it; once TALL peptides attach their biological red flags, immune cells flood into the tumor environment and begin killing those cells. Because TALL is tumor-cell specific, it leaves healthy cells untouched, reducing the potential for serious side effects.

Validation

Pre-clinical research evaluating TALL demonstrates that liposomes accumulated in targeted cancer cells and these cells were subsequently flagged with measles peptide. This generated a rapid and robust immune system response against the targeted tumor cells and a significant reduction in tumor growth.

Early research also suggests that the TALL system could greatly expand the benefits of existing cancer immunotherapies, including checkpoint inhibitors (CKIs). These drugs are rapidly becoming standard of care for many cancer types because – in those cancers that are readily recognized by the immune system and generate a significant immune response – they are very effective. Unfortunately, about 80 percent of cancers don’t naturally generate a significant immune system reaction. CKIs are far less effective in these patients.

“By helping the immune system more readily recognize these cancers, TALL can overcome this drawback. For example, in pre-clinical studies looking at breast and pancreatic cancers, combining TALL with a leading CKI led to a 90 percent reduction in tumor volumes as compared to using CKI alone.”

Partner with us

SRI Biosciences partners with commercial companies through research collaborations that lead to option and licensing agreements for further commercialization. We are actively seeking partners for the TALL program. For additional information and/or to explore partnership opportunities, please contact SRI Biosciences at biosciences@sri.com.

DECEMBER 2020

Share this

How can we help?

Once you hit send…

We’ll match your inquiry to the person who can best help you.

Expect a response within 48 hours.

Career call to action image

Make your own mark.

Search jobs

Our work

Case studies

Publications

Timeline of innovation

Areas of expertise

Institute

Leadership

Press room

Media inquiries

Compliance

Careers

Job listings

Contact

SRI Ventures

Our locations

Headquarters

333 Ravenswood Ave
Menlo Park, CA 94025 USA

+1 (650) 859-2000

Subscribe to our newsletter


日本支社
SRI International
  • Contact us
  • Privacy Policy
  • Cookies
  • DMCA
  • Copyright © 2023 SRI International
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}